Early Vaccine Approval Allows Moderna (MRNA) to Take Extra Market Share, May Drive Increased Pricing and Additional $2B-$5B in Sales - Cowen
Tweet Send to a Friend
Cowen analyst Tyler Van Buren reiterated a Market Perform rating and $200.00 price target on Moderna (NASDAQ: MRNA), following announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
